Today CHPA submitted a citizen petition to the U.S. Food and Drug Administration urging the agency to exercise its existing statutory authority to swiftly issue regulations that establish a clear pathway for manufacturers to lawfully market cannabidiol in dietary supplements.
This week, the four leading trade associations representing the U.S. dietary supplement industry joined forces to urge Congress to take action to ensure consumer safety and provide legal clarity in the CBD product marketplace.
As many dietary supplement products are being marketed as containing cannabidiol (CBD), CHPA has an interest in this subject and we presented oral comments at FDA’s May 31, 2019, public hearing. These written comments supplement our oral remarks.
CHPA supports efforts to encourage FDA to develop a legal path for CBD as a new dietary ingredient. Hemp oil is already an appropriate dietary ingredient.
CHPA has reviewed the findings of the meeting of the World Health Organization Expert Committee on Drug Dependence. CHPA agrees with the Committee's recommendations.
Learn about CHPA's current slate of federal legislative priorities including OTC regulatory reform, dietary supplement regulation modernization, supply chain and product integrity, and more.
